MedWatch

Leo Pharma announces new results for biologic hope

New phase III data from a study of one of Leo Pharma’s biologic drugs, Kyntheum, show significant benefits from long-term treatment with the drug.

At the European Academy of Dermatology (EADV) annual congress, the Danish company Leo Pharma presented new data for the biologic drug Kyntheum.

The results come from a phase III study of the drug, which is a biologic treatment for people with moderate-to-severe plaque psoriasis. The drug has already been granted marketing authorization in the EU but the new results will strengthen the solid data that ensured the approval for Leo Pharma. And this is needed, because treatment of psoriasis is a lucrative and very popular disease area just now.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier